title: Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.
abstract: Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.
authors.affiliation: INSERM; UMR892; Nantes, France ; CNRS; UMR6299; Nantes, France ; Université de Nantes; Nantes, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Fonteneau
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guillerme
authors.forename: Frédéric
authors.initials: F
authors.lastname: Tangy
authors.forename: Marc
authors.initials: M
authors.lastname: Grégoire
keywords: cytotoxic CD8+ T cell; measles virus vaccine; myeloid DC; oncolytic virus; plasmacytoid DC; tumor antigen